CD8+ T cell mediated inhibition of HIV-1 replication in Elite Suppressors
CD8+ T cell mediated inhibition of HIV-1 replication in Elite Suppressors
批准号:
8212175
负责人:
JOEL N BLANKSON
金额:
$32.15万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-02-15 至 2014-01-31
关键词:
Acquired Immunodeficiency SyndromeAllelesAntigen-Presenting CellsAutologousBiological AssayBypassCD4 Lymphocyte CountCD4 Positive T LymphocytesCD8B1 geneCell physiologyCellsCellular ImmunityConsensusDefective VirusesDetectionDevelopmentDiseaseDown-RegulationDropsFlow CytometryFrequenciesGaggingGrantHIVHIV AntigensHIV-1HLA-B AntigensHealthHistocompatibility Antigens Class IHumoral ImmunitiesImmune responseImmune systemImmunologicsIndividualInfectionIntegration Host FactorsKineticsLaboratoriesMHC Class I GenesMediatingMemoryMitogensModelingMutationNatural Killer CellsPatientsPeptidesPhysiologicalPlasmaPlayPredispositionProgressive DiseaseProliferatingProteinsProvirusesReportingResistanceRoleSpecificityT cell responseT-LymphocyteTestingTimeVaccinesViralViral Load resultViremiaVirusWorkantigen processingantiretroviral therapycytokinecytotoxicdesignfitnessimprovedin vivokillingsnovel strategiesrecombinant virusresponsetherapeutic vaccinevaccine development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Elite suppressors are HIV-1 infected patients who maintain viral loads of <50 copies/ml without antiretroviral therapy. We have recently shown for the first time that replication competent virus can be isolated from some of these individuals suggesting that immunologic control of replication competent HIV-1 is possible. The mechanism of control has yet to be defined in these patients, but we have shown that superior humoral immunity is not the cause of control in many ES and neither is an intrinsic resistance to HIV-1 infection. We have shown that provirus from these patients also do not have higher levels of APOBEC 3G/F mediated hypermutation. Taken together it appears that superior HIV-specific cellular immunity plays a key role in the control of viremia in elite suppressors. While the mechanism of CD8+ T cell mediated control is unknown, it has been shown that elite suppressors and patients with progressive disease have similar frequencies of HIV-specific CTL. However, it has recently been shown that unstimulated CD8+ T cells from elite suppressors, but not patients with progressive disease, are able to control the replication of a laboratory strain of HIV-1 in autologous CD4+ T cells. This is a physiological model since the CD8+ T cells are not activated prior to being used in the assay and the CD4+ T cells process and present HIV antigens (as opposed to peptides being added to the cells in culture). The objective of this proposal is to determine the mechanisms by which this CD8+ T cell mediated control of this replication competent virus is achieved. We plan to identify the major subset of CD8+ T cells involved in this control. We will also distinguish between cytotoxic killing of target cells and non-cytotoxic mediated suppression of viral replication. We will define the kinetics of the CD8+ T cell mediated control and determine whether Nef mediated down regulation of MHC class I proteins is a mechanism used by the virus to evade this control of viral replication. This work will be important for the development of vaccines that can be used to improve the HIV specific immune responses in HIV-1 infected individuals. This may allow some patients to control the virus without antiretroviral therapy for prolonged periods of time. PUBLIC HEALTH RELEVANCE: Most patients infected with HIV-1 will develop a drop in their CD4 counts and frank AIDS as the virus replicates and destroys the immune system. A unique group of untreated HIV-1-infected patients, termed Elite Suppressors (ES) are able to completely control the virus and do not develop AIDS (1-3). This project plans to determine how CD8+ T cells from ES control the virus; the results may be applicable to the development of an effective HIV-1 vaccine.
期刊论文(15)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Evolution of the HIV-1 nef gene in HLA-B*57 positive elite suppressors.
HLA-B*57 阳性精英抑制基因中 HIV-1 nef 基因的进化。
DOI:
10.1186/1742-4690-7-94
发表时间:
2010
期刊:
Retrovirology
影响因子:
3.3
作者:
[Salgado,Maria, Brennan,TimothyP, O'Connell,KarenA, Bailey,JustinR, Ray,StuartC, Siliciano,RobertF, Blankson,JoelN]
通讯作者:
Blankson,JoelN
Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors.
循环单核细胞并不是精英抑制因子中 HIV-1 的主要储存库。
DOI:
10.1128/jvi.05409-11
发表时间:
2011
期刊:
Journal of virology
影响因子:
5.4
作者:
[Spivak,AdamM, Salgado,Maria, Rabi,SAlireza, O'Connell,KarenA, Blankson,JoelN]
通讯作者:
Blankson,JoelN
DOI:
10.1038/ncomms1697
发表时间:
2012-03-06
期刊:
Nature communications
影响因子:
16.6
作者:
[]
通讯作者:
HIV type 1-mediated downregulation of HLA-B*57/B*5801 proteins on elite suppressor CD4+ T cells.
HIV 1 型介导的精英抑制 CD4 T 细胞上 HLA-B*57/B*5801 蛋白的下调。
DOI:
10.1089/aid.2010.0144
发表时间:
2011
期刊:
AIDS research and human retroviruses
影响因子:
1.5
作者:
[Sampah,MaameEfuaS, Ceccato,ChristinaM, Blankson,JoelN]
通讯作者:
Blankson,JoelN
Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection.
来自 HIV-1 阳性精英抑制因子的未刺激的初级 CD4 T 细胞完全容易受到 HIV-1 的进入和生产性感染。
DOI:
10.1128/jvi.01721-10
发表时间:
2011
期刊:
Journal of virology
影响因子:
5.4
作者:
[Rabi,SAlireza, O'Connell,KarenA, Nikolaeva,Daria, Bailey,JustinR, Jilek,BenjaminL, Shen,Lin, Page,KathleenR, Siliciano,RobertF, Blankson,JoelN]
通讯作者:
Blankson,JoelN
共 7 条
Eradication of clonally expanded CD4+ T cells
-
批准号:10621808
-
项目类别:
-
资助金额:$20.47万
-
财政年份:2022
-
负责人:JOEL N BLANKSON
-
依托单位:
Eradication of clonally expanded CD4+ T cells
-
批准号:10548015
-
项目类别:
-
资助金额:$24.56万
-
财政年份:2022
-
负责人:JOEL N BLANKSON
-
依托单位:
mRNA vaccine responses in PLWH
-
批准号:10687989
-
项目类别:
-
资助金额:$20.47万
-
财政年份:2022
-
负责人:JOEL N BLANKSON
-
依托单位:
mRNA vaccine responses in PLWH
-
批准号:10402541
-
项目类别:
-
资助金额:$24.56万
-
财政年份:2022
-
负责人:JOEL N BLANKSON
-
依托单位:
Optimization of high throughput viral outgrowth assays for the detection of HIV-1 reservoirs
-
批准号:10177855
-
项目类别:
-
资助金额:$40.94万
-
财政年份:2018
-
负责人:JOEL N BLANKSON
-
依托单位:
A mouse viral outgrowth assay for the detection of residual HIV-1 reservoirs
-
批准号:9298573
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2015
-
负责人:JOEL N BLANKSON
-
依托单位:
A mouse viral outgrowth assay for the detection of residual HIV-1 reservoirs
-
批准号:8965588
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2015
-
负责人:JOEL N BLANKSON
-
依托单位:
Phenotypic analysis of latently infected CD4+ T cells.
-
批准号:8713921
-
项目类别:
-
资助金额:$20.25万
-
财政年份:2013
-
负责人:JOEL N BLANKSON
-
依托单位:
Phenotypic analysis of latently infected CD4+ T cells.
-
批准号:8610757
-
项目类别:
-
资助金额:$22.84万
-
财政年份:2013
-
负责人:JOEL N BLANKSON
-
依托单位:
Analysis of HIV-1 in mucosal tissue in elite suppressors
-
批准号:8209611
-
项目类别:
-
资助金额:$23.43万
-
财政年份:2011
-
负责人:JOEL N BLANKSON
-
依托单位:
Analysis of HIV-1 in mucosal tissue in elite suppressors
-
批准号:8333997
-
项目类别:
-
资助金额:$19.88万
-
财政年份:2011
-
负责人:JOEL N BLANKSON
-
依托单位:
CD8+ T cell mediated inhibition of HIV-1 replication in Elite Suppressors
-
批准号:7684560
-
项目类别:
-
资助金额:$32.8万
-
财政年份:2009
-
负责人:JOEL N BLANKSON
-
依托单位:
CD8+ T cell mediated inhibition of HIV-1 replication in Elite Suppressors
-
批准号:8013541
-
项目类别:
-
资助金额:$32.15万
-
财政年份:2009
-
负责人:JOEL N BLANKSON
-
依托单位:
CD8+ T cell mediated inhibition of HIV-1 replication in Elite Suppressors
-
批准号:7769479
-
项目类别:
-
资助金额:$32.47万
-
财政年份:2009
-
负责人:JOEL N BLANKSON
-
依托单位:
CD8+ T cell mediated inhibition of HIV-1 replication in Elite Suppressors
-
批准号:8879353
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2008
-
负责人:JOEL N BLANKSON
-
依托单位:
Characterization of HIV excape mutants and T cell responses in elite suppressors
-
批准号:7474853
-
项目类别:
-
资助金额:$28.12万
-
财政年份:2007
-
负责人:JOEL N BLANKSON
-
依托单位:
Latent virus and HIV-1 specific immunity in LTNPs
-
批准号:7110268
-
项目类别:
-
资助金额:$12.61万
-
财政年份:2002
-
负责人:JOEL N BLANKSON
-
依托单位:
Latent virus and HIV-1 specific immunity in LTNPs
-
批准号:6450960
-
项目类别:
-
资助金额:$11.53万
-
财政年份:2002
-
负责人:JOEL N BLANKSON
-
依托单位:
Latent virus and HIV-1 specific immunity in LTNPs
-
批准号:6787316
-
项目类别:
-
资助金额:$12.61万
-
财政年份:2002
-
负责人:JOEL N BLANKSON
-
依托单位:
Latent virus and HIV-1 specific immunity in LTNPs
-
批准号:6924043
-
项目类别:
-
资助金额:$12.61万
-
财政年份:2002
-
负责人:JOEL N BLANKSON
-
依托单位:
海外基金